Clinerion Expands in Poland
EMC Szpitale augments Clinerion’s patient coverage in Poland by joining the Patient Network Explorer platform. Patients at the hospital group will gain access to clinical trials, and actively support the launch of medical treatments.
Joining Clinerion’s hospital partner network gives EMC Spitale visibility to trial sponsors on their readiness to participate in clinical research on an international level. EMC Szpitale patients will gain access to clinical care as the Patient Network Explorer draws international clinical studies to the hospital group, directly to the patients.
EMC Szpitale operates 11 hospitals and 19 outpatient clinics, providing primary and specialized medical care to over one million patients across Poland. EMC Szpitale specializations include advanced diagnostics to comprehensive hospital treatment in gastroenterology, rehabilitation, urology, orthopedics, general surgery, gynecology, obstetrics and geriatric care. Currently, the hospital group is running 37 different clinical trials.
EMC Szpitale uses an artificial intelligence technology supporting oncologists in choosing optimal cancer treatments. With their focus on geriatric care, EMC Szpitale is a partner of the nationwide social campaign ‘Understand Old Age’. The hospital group pioneers innovative ways of thinking and operational processes. The implementation of Lean Management at the hospital in Lubin has been recognized with the award for the Innovative Hospital 2017 in the Success of the Year in Healthcare competition.
“We care for our patients. Everyday. In a better way. That’s why we work to increase interest and enrollment in clinical trials to ultimately ensure greater availability of innovative therapies for our patients,” says Anna Szewczuk-Lebska, spokesperson for EMC Szpitale.
“Sponsors are looking for trials sites with the highest levels of care, therapeutic experience and clinical experts,” says Ian Rentsch, Clinerion CEO. “EMC Spitale’s broad therapeutic coverage and geographical situation make it a great partner for them and for Clinerion.”
To learn more go to www.clinerion.com
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Patient Engagement Platform Checklist
November 22nd 2024Modern clinical trials are more complex than ever, and one significant reason is the increased focus on patient engagement. Incorporating a patient engagement platform into your clinical trial enhances the patient experience and can lead to more successful trials with stronger, more reliable outcomes. We put together this helpful checklist of key features to look out for when choosing a platform for your study.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
